Wiltrom announced on the 20th that it had successfully completed a NT$270 million private placement. Amed Ventures, the venture capital arm of Pegatron, invested NT$130 million at NT$26.8 per share, acquiring over 12% equity in Wiltrom. This makes Amed Ventures the company’s second-largest shareholder. Based on Wiltrom’s closing price of NT$31.35 yesterday, the placement reflects a discount of approximately 14.5%. Amed Ventures is expected to gain a board seat. The funds raised will be used to expand Wiltrom’s product footprint in Europe and the United States.
Long-term partner Intai Technology also participated with a NT$100 million investment, while Wiltrom’s management team contributed NT$40 million. Wiltrom’s minimally invasive orthopedic devices currently have a 100% adoption rate in Taiwan’s medical centers. The funds raised will enhance Wiltrom’s efforts to penetrate the European and U.S. markets, with a particular focus on its Tripod-Fix Expandable Vertebral Reinforcement System, which aims to deepen its presence in Europe and expand into the U.S.
Wiltrom Chairman Huang-Chien Liang stated that the involvement of Amed Ventures and the continued support of Intai Technology bring valuable resources and expertise, enabling Wiltrom to accelerate its expansion into the European and U.S. markets.
Wiltrom disclosed that nearly 600 Tripod-Fix implants were sold overseas last year, and the company expects sales to more than double this year. The European vertebral compression fracture treatment market is valued at $71 billion, with a compound annual growth rate of 11.82%.
To achieve its goals, Wiltrom plans to establish a sales team in Germany to secure a 10% market share in the European vertebral compression mechanical implants market and 5% market share in the spinal fusion market. The company will collaborate with local sales teams, prominent clinical physicians, and key opinion leaders in Europe, while expanding hospital networks to enhance its market position.
For the U.S. market, Wiltrom plans to work with American clinical physicians to identify products that meet clinical needs, align with high-growth market trends, and possess significant market potential. Through investments, licensing, and co-development, Wiltrom aims to leverage Taiwan-U.S. advantages to establish partnerships and gain access to the world’s largest medical device market.
Amed Ventures, with over a decade of experience in the U.S. and Taiwan medical industries, will provide Wiltrom with critical strategic guidance and resources for U.S. market expansion. This includes connecting Wiltrom to U.S. market needs and introducing financial and strategic partners.
As Wiltrom’s long-term investment partner, Intai Technology brings extensive expertise in medical device manufacturing and robust industry resources. Intai’s continued investment demonstrates strong confidence in Wiltrom’s growth potential and will ensure reliable support for the production of Wiltrom’s innovative products.
Resource: 台微醫私募 和碩參與
